We protect your health through science
Investigation
Human Papillomavirus
Research Lines
Content with Investigacion .
B) Study of the distribution and dynamics of HPV infections in risk groups. There are some particularly vulnerable groups, some of them difficult to access (sex workers, transgender groups, etc.), in which HPV infections deserve special attention. The prevalence of HPV infection is especially high in people living with HIV and/or among men who have sex with men. Knowledge of the distribution and dynamics of infections is especially interesting in these groups, as they may help to improve current algorithms for the prevention of anogenital cancer.
C) Study of infection by HPV genotypes and their relationship with progression to neoplastic processes. The oncogenic capacity of some HPV genotypes and their involvement in the production of anogenital cancer is well known. In addition, there are other oncological processes, such as non-melanoma skin cancer, in which HPV could be implicated. Thus, members of the gamma-24 HPV species have recently been associated with skin cancer. It is to be hoped that the appearance of new genotypes and the performance of more extensive studies may lead to the identification of new associations between HPV and neoplastic processes.
D) Study of co-infections by different HPV genotypes. The presence of co-infections of different HPV genotypes is a very frequent finding, both in skin samples and in different mucous membranes. The great genetic diversity of HPV limits the ability of classical molecular methods to perform a comprehensive detection and study of the genotypes present. However, the use of massive sequencing makes it possible to eliminate some of these biases and to obtain more detailed information on the existing HPV populations, as well as to analyze interactions between the different genotypes.
E) Description of new HPV genotypes/variants. Currently at the International HPV Reference Center (Karolinska Institute, Sweden) more than 220 HPV genotypes are described, distributed in 5 different genera. However, improved molecular detection techniques, as well as the use of massive sequencing, are allowing this number to increase rapidly. The study of new genotypes and variants is essential for the validation and quality control of available diagnostic methods. Similarly, their characterization and the study of possible associations of HPV with pathologies other than those already known is a field of great interest for research.
Research projects
Content with Investigacion .
Título: Impact of vaccination against Human Papillomavirus in Spain: Studye of the distribution of genotypes and its application in surveillance. Principal Investigator: Horacio Gil. Starting/End dates: 2024-2026. Funding Entity: Acción Estratégica de Salud Intramural (AESI) del Instituto de Salud Carlos III. Project Reference: PI23CIII/00006.
Título: Effect of feminizing therapy on immune response in transgender women. Principal Investigator: Victor Manuel Sánchez Merino. Collaborating Investigator: Horacio Gil. Starting/End dates:2025-2027. Funding Entity: Acción Estratégica de Salud Intramural (AESI) del Instituto de Salud Carlos III. Project Reference: PI24CIII/00031.
Publications
Where are we with monoclonal antibodies for multidrug-resistant infections?
Where are we with monoclonal antibodies for multidrug-resistant infections? McConnell MJ. Drug Discov Today. 2019 May;24(5):1132-1138. doi: 10.1016/j.drudis.2019.03.002.
PUBMEDPeptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii
Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii. Gil-Marqués ML, Moreno-Martínez P, Costas C, Pachón J, Blázquez J, McConnell MJ. J Antimicrob Chemother. 2018 Nov 1;73(11):2960-2968. doi: 10.1093/jac/dky289.
PUBMEDImmunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection
Immunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection. Pulido MR, García-Quintanilla M, Pachón J, McConnell MJ. Vaccine. 2018 Jul 5;36(29):4153-4156. doi: 10.1016/j.vaccine.2018.05.113.
PUBMEDPhenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii
Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii. Carretero-Ledesma M, García-Quintanilla M, Martín-Peña R, Pulido MR, Pachón J, McConnell MJ. Virulence. 2018 Dec 31;9(1):930-942. doi: 10.1080/21505594.2018.1460187.
PUBMEDCurso de Gestión de Calidad y Buenas Prácticas de Laboratorio. Ed. 3
Grammatico JP, Cuevas L (Edits.) y Grupo de expertos de la Organización Panamericana de la Salud OPS/OMS. Curso de Gestión de Calidad y Buenas Prácticas de Laboratorio. Ed. 3. OPS/OMS;. Washington, D.C., 2016. Disponible en: “http://iris.paho.org/xmlui/handle/123456789/31168”. ISBN: 978-92-75-11906-8
Gestión de la Calidad para laboratorios de ensayo. 1ª ed.
Grammatico JP, Cuevas L (Edits.). Gestión de la Calidad para laboratorios de ensayo. 1ª ed. Conicet-Madri+d; Buenos Aires, 2011. Disponible en: “http://www.madrimasd.org/Laboratorios/Documentos/Red-Laboratorios/documentos/Gest_Calidad_Ensayo.pdf”. ISBN: 978-950-692-095-1
Curso de Gestión de Calidad y Buenas Prácticas de Laboratorio.
Grupo de expertos de la Organización Panamericana de la Salud OPS/OMS. Curso de Gestión de Calidad y Buenas Prácticas de Laboratorio. OPS; Documentos Técnicos THR/HT 2009/001. Washington, D.C., 2009. ISBN: 978-92-75-32977-1
Guía Latinoamericana para la implementación de Código de Ética en los laboratorios de salud.
Grupo de expertos de la Organización Panamericana de la Salud (OPS/OMS). Guía Latinoamericana para la implementación de Código de Ética en los laboratorios de salud. Organización Panamericana de la Salud. Documentos Técnicos. Políticas y Regulación. THS/EV-2007/001; 2007. ISBN: 92-7-532702-5
HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization
Valle-Millares D; Brochado-Kith O; Gómez-Sanz A; et al; Fernández-Rodríguez A (AC). (17/17). 2021. Biomedicine and Pharmacotherapy. Elsevier.
DOIIdentification of HIV-1 circulating BF1 recombinant form (CRF75_BF1) of Brazilian origin that also circulates in Southwestern Europe
Bacqué J, Delgado E, Gil H, Ibarra S, Benito S, García-Arata I, Moreno-Lorenzo M, Sáez de Arana E, Gómez-González C, Sánchez M, Montero V and Thomson MM. Front Microbiol. 2023. 14: 1301374
PUBMED DOIFactors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.
Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM and Spanish Group for the study of antirretroviral drug Resistance. Front Microbiol. 2022. 13:1051096
PUBMED DOITransmission clusters, predominantly associated with men who have sex with men, play a main role in the propagation of HIV-1 in Northern Spain (2013-2018).
Gil H, Delgado E, Benito S, Georgalis L, Montero V, Sánchez M, Cañada-García JE, García-Bodas E, Diaz A, Thomson MM and Spanish group of the study of new HIV diagnoses. Front Microbiol. 2022. 13:782609
PUBMED DOIPotent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses
Beltran-Pavez C, Bontjer I, Gonzalez N, Pernas M, Merino-Mansilla A, Olvera A, Miro JM, Brander C, Alcami J, Sanders RW, Sanchez-Merino V, Yuste E; J Virol. 2022 Jan 12;96(1):e0134321.
PUBMED DOIPermanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure
Casado C, Galvez C, Pernas M, Tarancon-Diez L, Rodriguez C, Sanchez-Merino V, Vera M, Olivares I, De Pablo-Bernal R, Merino-Mansilla A, Del Romero J, Lorenzo-Redondo R, Ruiz-Mateos E, Salgado M, Martinez-Picado J, Lopez-Galindez C; Sci Rep. 2020 Feb 5;10(1):1902
PUBMED DOIGuiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant
Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V; PLoS One. 2018 Dec 19;13(12):e0208345
PUBMED DOIDetection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection
Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E; J Virol. 2016 May 12;90(11):5231-5245
PUBMED DOIContent with Investigacion .
-
Horacio Gil Gil
Research Scientist
ORCID code: 0000-0002-7114-6686
Degree in Veterinary Medicine in 1995 and PhD in Veterinary Medicine in 2002 from the University of Zaragoza. He did his PhD thesis at NEIKER Tecknalia (Derio, Vizcaya) and the National Center for Microbiology of Instituto de Salud Carlos III (CNM-ISCIII, Majadahonda, Madrid) on the biological cycle of Lyme disease in the Basque Country. After that, he developed his postdoctoral training in different aspects of the pathogenesis of tularemia at the Center for Infectious Diseases, Stony Brook University, New York (USA) for 3 years. In December 2005, he joined the Reference and Research Laboratory in Special Pathogens of the CNM-ISCIII where he developed diagnostic, reference and research activities, in Bartonella, Leptospira and pathogens of interest in bioterrorism. Between 2014-2016 he participated in the European Program for the Training of Microbiologists in Public Health (EUPHEM), organized by the European Centre for Disease Prevention and Control. During this program, he participated in an international mission for the investigation of a cholera outbreak in Ghana, proposed by the Bernhard Nocht Institute for Tropical Diseases in Hamburg (Germany). In December 2016, he worked as a laboratory consultant for the World Health Organization at their office in Phnom Penh (Cambodia). Subsequently, he worked one year with Médecins Sans Frontières as director and quality manager of the TB laboratory in Nukus (Uzbekistan).
In 2019, he joined the HIV Variability and Biology Unit at CNM-ISCIII, where he developed different reference and research activities, including his contribution to the molecular epidemiological surveillance of HIV-1 in Spain and the study of HIV-1 antiretroviral resistance. Since September 2022 he has been leading the Human Papillomavirus Unit at the CNM-ISCIII. -
Alicia Inés García Señán
Predoctoral Student UNED
Degree in Pharmacy in 2013 from the Complutense University of Madrid. She completed specialized health training in Microbiology and Parasitology at the Complejo Asistencial Universitario de Salamanca (2014-2018). During this period he studied a master's degree in Tropical Diseases at the University of Salamanca (2016). She has developed her professional activity as a clinical microbiologist at the Hospital de Santa Bárbara (Soria) (2018), Hospital Universitario Vall d'Hebrón (Barcelona) (2019-2022), and Hospital Central de la Defensa (Gómez Ulla) C.S.V.E, since 2022. In September 2024 she has started PhD studies at the Human Papillomavirus Unit of the CNM-ISCIII.
-
Manuela Rodríguez Vargas
Técnico de Laboratorio
List of staff
Additional Information
Diagnosis/Reference: detection and genotyping of the Human Papillomavirus, tests offered at https://cnm-laboratorios.isciii.es/.
For additional studies contact the laboratory.
• Molecular epidemiology of infections caused by HPV in the general population and in different risk groups.
• Surveillance of the distribution of genotypes in the population to monitor the effectiveness of vaccination against HPV.
• Development of new methodology for the diagnosis and characterization of infections caused by HPV.
Diagnosis/Reference: detection and genotyping of the Human Papillomavirus, tests offered at https://cnm-laboratorios.isciii.es/.
For additional studies contact the laboratory.
• Molecular epidemiology of infections caused by HPV in the general population and in different risk groups.
• Surveillance of the distribution of genotypes in the population to monitor the effectiveness of vaccination against HPV.
• Development of new methodology for the diagnosis and characterization of infections caused by HPV.